The 2019 Nobel Prize in Medicine has been awarded to William Kaelin, Gregg Semenza and Peter Ratcliffe for their research on adapting cells to variable oxygen supply. More specifically, they solved the mystery of the molecular mechanism that caused hypoxia adaptation.
This year, three people are rewarded with the Nobel prize of Medicine or Physiology. These are William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for " their discoveries about how cells perceive and adapt to oxygen availability ". They unveiled the molecular mechanisms regulating the activity genetic, in response to variations in oxygen level. Their work thus explains a process of essential adaptation of the cells, and gives new possibilities to fight theanemia, the cancers, and other diseases that involve cellular perception of theoxygen.
Oxygen sensing is central to a large number of diseases. The discoveries made by this year's #NobelPrize laureates have fundamental importance for physiology and have paved the way for promising new strategies to fight anemia, cancer and many other diseases. pic.twitter.com/I7oecTXHGX
– The Nobel Prize (@NobelPrize) October 7, 2019
Who are the Nobel Prize winners of Medicine 2019?
William G. Kaelin Jr. is a professor of medicine at Harvard University, specializing in oncology. In 2016, he received the Lasker Award for his research, a prize awarded to people making major advances in medicine. He works in particular on protein tumor suppressors.
Sir Peter J. Ratcliffe is a doctor as well as a cellular and molecular biologist at John Radcliffe Hospital, Oxford University. His Nobel Prize rewards his work on cellular reactions tohypoxiathat is to say, the absence of a sufficient supply of oxygen in a part or the whole body.
Gregg L. Semenza was already known for his discovery of HIF-1, a factor in transcription which allows cancer cells to adapt to environments with low oxygen. He is a professor of genetic medicine, chemistry biological, medicine, pediatrics, and also radiation oncology and molecular radiation.
BREAKING NEWS:
The 2019 #NobelPrize William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza, "For their discoveries of how cells sense and adapt to oxygen availability." pic.twitter.com/6m2LJclOoL– The Nobel Prize (@NobelPrize) October 7, 2019
Why are they rewarded? The beginning of an investigation
The Nobel Prize in Medicine is awarded to them for their explanation of the molecular mechanism governing the cellular response to the variations of oxygen, and more precisely to the absence of oxygen.
A key answer tohypoxia is the increase in levels of erythropoietin (COOL), a hormone mainly produced by kidneys. It stimulates the proliferation of stem cells precursors of erythrocytes, or "red blood cells", more commonly referred to as " Red cells ". Thus, increased levels of EPO lead to increased production of erythrocytes. Semenza was working on how oxygen levels regulate the uncomfortable EPO, just like Ratcliffe. They both independently found that the mechanism of oxygen perception was present in all tissues, not just in the kidneys where EPO is produced. It would be induced by a segment ofDNA located next to the EPO gene.
Subsequently, Semenza identified a protein complex that binds to this DNA segment in an oxygen-dependent manner: the Hypoxia-inducible factor (HIF). In 1995, he discovered the Genoa encoding HIF, which is composed of two protein sub-complexes: HIF-1α and ARNT. Thus, when the oxygen levels are high, the cells contain little HIF-1α. Whereas if oxygen levels are low, the amounts of HIF-1α increase to regulate the EPO on the rise. A mechanism for regulating HIF-1α is degradation by proteasome, a complex enzyme. In order for the proteasome to recognize what it needs to degrade, a small peptic is attached to proteins: theubiquitin. But how can ubiquitin cling to HIF-1α in an oxygen-dependent way?
Crucial discovery and Nobel Prize in Medicine approaches
In his research on Von Hippel-Lindau disease (VHL disease), Kaelin was able to show that cancer cells have abnormally high levels of genes regulated by the disease.hypoxia, if they do not have a functional VHL gene. When the functional gene is reintroduced into the celllevels return to normal. Thanks to others teams of researchersit has been known that the VHL protein is part of a complex that labels other proteins with ubiquitin, causing them to be degraded. These findings allowed Ratcliffe to demonstrate that VHL interacts with HIF-1α and is necessary for HIF-1α to degrade when oxygen levels are normal.
A mystery remained unresolved: how does the oxygen level regulate the interaction between VHL and HIF-1α? In 2001, Kaelin and Ratcliffe published two articles simultaneously highlighting that under normal oxygen levels, hydroxyl groups are added at two specific positions of HIF-1α. This allows VHL to recognize HIF-1α and to grip it, to bring about its degradation by the proteasome. However, the addition of the hydroxyl groups is carried out by prolyl hydroxylases, which are enzymes… sensitive to oxygen! Ratcliffe was also able to identify the prolyl hydroxylases responsible. It was also put in light that the genetic activation function of HIF-1α is regulated by an oxygen-dependent hydroxylation. Treasure hunt done! The chest held three Nobel Prizes of Medicine or Physiology.
2019 Medicine Laureates William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza have identified molecular machinery that regulates the activity of genes in response to varying levels of oxygen.#NobelPrizepic.twitter.com/LiExfH74rh
– The Nobel Prize (@NobelPrize) October 7, 2019
- Hypoxia causes increased amounts of EPO, which stimulates the production of erythrocytes.
- HIF (Hypoxia-inducible factor) is composed of two sub-complexes: HIF-1α and ARNT. When the oxygen level is low, the level of HIF-1α increases to regulate the EPO on the rise. The amount of HIF-1α is regulated by the proteasome, which degrades the proteins labeled with ubiquitin.
- The VHL protein interacts with HIF-1α and is necessary for HIF-1α to degrade when the oxygen level is normal.
- VHL clings to HIF-1α when prolyl hydroxylases (oxygen-sensitive enzymes) add two hydroxyl groups.
- The genetic activation function of HIF-1α is regulated by an oxygen-dependent hydroxylation.
Interested in what you just read?
Subscribe to the newsletter The daily : our latest news of the day.
It will interest you too
Source link
https://www.futura-sciences.com/sante/actualites/prix-nobel-medecine-prix-nobel-medecine-2019-cellules-adaptent-absence-oxygene-77835/